BioPharmSignal logoBioPharmSignal

Biotech News

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTC Therapeutics, Inc. (PTCT)PTC Therapeutics, Inc.Conference / presentation

WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Jefferies Global Healthcare Conference Monday, Nov. 16 at 11 a.m. GMT / 6 a.m. ET Citi 2026 Global Healthcare Conference Tuesday, Dec.

Related news

ARWRArrowhead Pharmaceuticals2026-09-03 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

PHARPharming Group2026-09-09 06:00 EST

Pharming Group to participate in September investor conferences

BCRXBioCryst Pharmaceuticals2026-11-04 21:01 EST

BioCryst to Present at Upcoming Investor Conferences

BCRXBioCryst Pharmaceuticals2026-09-01 11:00 EST

BioCryst to Present at Upcoming Investor Conference

RCKTRocket Pharmaceuticals2026-10-15 11:00 EST

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

EDITEditas Medicine2026-10-14 13:00 EST

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

TARAProtara Therapeutics2026-09-08 20:05 EST

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

ETONEton Pharmaceuticals2026-08-27 10:50 EST

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

PTCTPTC Therapeutics, Inc.2026-11-03 12:00 EST

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

PTCTPTC Therapeutics, Inc.2026-10-30 20:30 EST

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

PTC Therapeutics, Inc.

Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases. Commercial Portfolio Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise....

Recent company news

PTCTPTC Therapeutics, Inc.2026-11-03 12:00 EST

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

PTCTPTC Therapeutics, Inc.2026-11-02 13:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTCTPTC Therapeutics, Inc.2026-10-30 20:30 EST

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTCTPTC Therapeutics, Inc.2026-10-29 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

PTCTPTC Therapeutics, Inc.2026-10-15 12:00 EST

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

Stock data

Close
65.67 USD
Market cap
5.66B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States